Search Results - "Juric, D."

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 by André, F., Ciruelos, E.M., Juric, D., Loibl, S., Campone, M., Mayer, I.A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., Inoue, K., Pápai, Z., Takahashi, M., Ghaznawi, F., Mills, D., Kaper, M., Miller, M., Conte, P.F., Iwata, H., Rugo, H.S.

“…Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal…”
Get full text

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial by Kalinsky, K., Diamond, J.R., Vahdat, L.T., Tolaney, S.M., Juric, D., O'Shaughnessy, J., Moroose, R.L., Mayer, I.A., Abramson, V.G., Goldenberg, D.M., Sharkey, R.M., Maliakal, P., Hong, Q., Goswami, T., Wegener, W.A., Bardia, A.

“…Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC)…”
Get full text

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) by Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P.L., Cortes, J., Hyman, D.M., Juric, D., Krop, I., Bieche, I., Saura, C., Sotiriou, C., Cardoso, F., Loibl, S., Andre, F., Turner, N.C.

“…Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of…”
Get full text

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer by Rugo, H.S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S.M., Jurado, J.C., Juric, D., Mayer, I., Ciruelos, E.M., Iwata, H., Conte, P., Campone, M., Wilke, C., Mills, D., Lteif, A., Miller, M., Gaudenzi, F., Loibl, S.

“…Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is approved in multiple countries for men and postmenopausal women with…”
Get full text

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer by Berchuck, J.E., Facchinetti, F., DiToro, D.F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Uson Junior, P.L.S., Maurer, J., Shroff, R.T., Pritchard, C.C., Wu, M.-J., Catenacci, D.V.T., Javle, M., Friboulet, L., Hollebecque, A., Bardeesy, N., Zhu, A.X., Lennerz, J.K., Tan, B., Borad, M., Parikh, A.R., Kiedrowski, L.A., Kelley, R.K., Mody, K., Juric, D., Goyal, L.

“…Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for…”
Get full text

A Front-Tracking Method for the Computations of Multiphase Flow by Tryggvason, G., Bunner, B., Esmaeeli, A., Juric, D., Al-Rawahi, N., Tauber, W., Han, J., Nas, S., Jan, Y.-J.

“…Direct numerical simulations of multiphase flows, using a front-tracking method, are presented. The method is based on writing one set of governing equations…”
Get full text

Role of Kidney Stones in Renal Pelvis Flow by Constante-Amores, C R, Kahouadji, L, Williams, J G, Turney, B W, Shin, S, Chergui, J, Juric, D, Moulton, D E, Waters, S L

“…Ureteroscopy is a commonly performed medical procedure to treat stones in the kidney and ureter using a ureteroscope. Throughout the procedure, saline is…”
Get more information

Resveratrol Prevents the Development of Pathological Cardiac Hypertrophy and Contractile Dysfunction in the SHR Without Lowering Blood Pressure by Thandapilly, Sijo J., Wojciechowski, Peter, Behbahani, John, Louis, Xavier L., Yu, Liping, Juric, Danijel, Kopilas, Melanie A., Anderson, Hope D., Netticadan, Thomas

“…Background Cardiac hypertrophy is a compensatory enlargement of the heart in response to stress such as hypertension. It is beneficial in reducing stress…”
Get full text

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer by Grinshpun, A., Ren, S., Graham, N., DeMeo, M.K., Wrabel, E., Carter, J., Tayob, N., Pereslete, A., Hamilton, E., Juric, D., Mayer, E.L., Tolaney, S.M., Krop, I.E., Metzger, O.

“…In most patients with advanced human epidermal growth factor receptor-2-positive (HER2+) breast cancer, anti-HER2 therapies fail due to the development of…”
Get full text

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial by André, F., Ciruelos, E.M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H.S., Iwata, H., Conte, P., Mayer, I.A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., Juric, D.

Get full text

A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies by Juric, D, Lopez, J, Rasco, D, Macarulla Mercadé, T, Xu, Q, Brittany, B, Kuida, K, Patel, C, Neuwirth, R, Enke, A, Zohren, F, Burris, H.A

“…Background: Sustained monotherapy of selective mTOR kinase inhibitors (mTORi) such as TAK-228 may be limited by pathway reactivation via feedback signaling…”
Get full text

484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080) by Kwak, E.L, Juric, D, Cleary, J.M, Cote, G, Hilton, J.F, Flaherty, K.T, Wood, K, Rance, C, Barrett, S, Shapiro, G.I

Get full text

342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors by Juric, D, Rodón, J, Bauer, T.M, Wainberg, Z, Tolaney, S, Modi, S, Martín, A. González, Hengelage, T, Melendez, M, Choudhury, S, Nauwelaerts, H, Bedard, P.L

Get full text

A Front-Tracking Method for Dendritic Solidification by Juric, Damir, Tryggvason, Grétar

“…We present a front-tracking method to simulate time dependent two-dimensional dendritic solidification of pure substances. The method is based on a finite…”
Get full text

75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressure by Castel, P, Juric, D, Griffith, M, Griffith, O.L, Won, H.H, Ainscough, B, Ellis, H, Ebbesen, S, Gopakumar, I, Quadt, C, Peters, M, Solit, D, Lowe, S.W, Mardis, E.R, Berger, M.F, Scaltriti, M, Baselga, J

Get full text

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer by Strickler, John H., Satake, Hironaga, George, Thomas J., Yaeger, Rona, Hollebecque, Antoine, Garrido-Laguna, Ignacio, Schuler, Martin, Burns, Timothy F., Coveler, Andrew L., Falchook, Gerald S., Vincent, Mark, Sunakawa, Yu, Dahan, Laetitia, Bajor, David, Rha, Sun-Young, Lemech, Charlotte, Juric, Dejan, Rehn, Marko, Ngarmchamnanrith, Gataree, Jafarinasabian, Pegah, Tran, Qui, Hong, David S.

“…In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a…”
Get full text

The fatty acid profile of vegetative Azotobacter vinelandii ATCC 12837 : growth phase-dependence by LARSEN, A, SLISKOVIC, I, JURIC, D, PINNOCK, C. L, KULLMAN, H, SEGSTRO, E, REINFELDS, G, EZE, M. O

“…Fatty acids of Azotobacter vinelandii ATCC 12837 were determined at various times during aerobic vegetative growth at 30 degrees C to provide baseline data for…”
Get full text

Cytokine-regulated secretion of nerve growth factor from cultured rat neonatal astrocytes by Juric, D M, Carman-Krzan, M

“…Interactions involved in the regulation of nerve growth factor (NGF) release by inflammatory cytokines: interleukin-1beta (IL-1beta), interleukin-6 (IL-6),…”
Get full text

491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors by Yap, T.A., Moore, K.N., Patel, M., Henick, B.S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., Juric, D.

Get full text

175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study by Cardoso, F., Juric, D., Lerebours, F., Krop, I., Ruiz Borrego, M., Neven, P., Park, Y.H., Yardley, D., Jhaveri, K., Arce, C., Gu, E., Akdere, M., Rugo, H.S.

Get full text